Jennifer Petter, PhD

Jennifer Petter, Ph.D., is a Founder & Chief Innovation Officer of Arrakis Therapeutics. An experienced drug hunter, scientist, and life science executive, Dr. Petter’s research has spanned different fields over the years, with a current focus on RNA at Arrakis. She is the author or co-author on over 50 papers and over 50 patents and/or patent applications. Prior to creating Arrakis, Dr. Petter was Vice President of Chemistry at Celgene. She joined Celgene after the acquisition of Avila Therapeutics, a startup, in 2012. She has also held roles at Mersana Therapeutics, Biogen, and the Sandoz Research Institute (now a part of Novartis). She is a member of the American Association of Cancer Research (AACR), the Society of Neuro-Oncology, and the RNA Society and an associate member of the American Society of Clinical Oncology (ASCO). Dr. Petter serves on the scientific advisory boards for Cygnal Therapeutics and PIC Therapeutics, and on the boards of directors for OUTBio and Theon Therapeutics. Dr. Petter received her bachelor’s degree from Dartmouth College and her Ph.D. from Duke University. She completed her post-doctorate research at Columbia University.